Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+"
Recruitment status was Recruiting
The biological response to treatment with tamoxifen in the preoperative situation is studying in this protocol. This study will enrolls patients with non-metastatic breast cancer HR +.
The relationship between the CYP2D6 polymorphism, pharmacokinetics and biological efficacy of TAM will be studied.
|Study Design:||Intervention Model: Single Group Assignment
Primary Purpose: Screening
|Official Title:||Phase II Study Evaluating According to the Polymorphism of CYP2D6, the Rate of Biological Response to Treatment With Tamoxifen (TAM) Administered in Pre-operative Situation in Patients With Breast Cancer Non Metastatic HR+"|
- the phenotype of gene involved in the metabolism of tamoxifem will be analysed [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||September 2009|
|Estimated Primary Completion Date:||September 2012 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01220076
|Centre Léon Berard||Recruiting|
|Lyon, France, 69000|
|Contact: Thomas Bachelot, Md +33 478 78 28 28.|
|Contact: Paul ¨Couttu, MD +33 1 56 24 55 00|
|Centre René Gauducheau||Recruiting|
|Saint Herblain, France, 44805|
|Contact: Mario Campone, MD +33240679900|